March 14 U.S. regulators have approved an
additional use of Bristol-Myers Squibb Co's blood clot
preventer Eliquis, to prevent blood clots in the legs and lungs
of patients who have undergone surgery to receive artificial
hips or knees.
The drug is already sold in partnership with Pfizer Inc
to prevent blood clots that can cause strokes in
patients with atrial fibrillation, an irregular heartbeat that
is most common in the elderly.
The drugmakers, in a joint release on Friday, said the U.S.
Food and Drug Administration had approved the new use, noting
that each year in the United States there are about 719,000
total knee replacement surgeries and 332,000 hip replacements.
After such surgeries, patients are at greater risk of
developing blood clots in the deep veins of the legs, which can
break free and travel to the lungs, where they can be fatal.
The new approval will help Eliquis to compete with Xarelto,
a similar drug from Johnson & Johnson and Bayer AG
that is also approved for use after knee and hip
replacements, as well as to prevent strokes among those with
Shares of Bristol Myers were down 0.4 percent, while Pfizer
shares rose 0.5 percent, both on the New York Stock Exchange.